| scholarly article | Q13442814 |
| P50 | author | Francesca Cicchetti | Q89283451 |
| Emmanuel Planel | Q90328587 | ||
| Giulia Cisbani | Q57167793 | ||
| Maud Gratuze | Q59195478 | ||
| P2860 | cites work | Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion | Q24339549 |
| Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments | Q24599152 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease | Q28242505 | ||
| Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 | Q28274687 | ||
| Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1 | Q28306183 | ||
| Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats | Q28587110 | ||
| Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Regional and cellular gene expression changes in human Huntington's disease brain | Q33233457 | ||
| Late onset of Huntington's disease | Q33621109 | ||
| Huntington's disease: from molecular pathogenesis to clinical treatment | Q33773061 | ||
| The selective vulnerability of striatopallidal neurons | Q33939097 | ||
| Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice | Q34017941 | ||
| Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment | Q34198357 | ||
| Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients | Q34470414 | ||
| Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. | Q34531481 | ||
| Huntingtin-protein interactions and the pathogenesis of Huntington's disease | Q35704403 | ||
| Role of tau protein in both physiological and pathological conditions. | Q35715199 | ||
| The role of tau in the pathological process and clinical expression of Huntington's disease | Q36066666 | ||
| CSF biomarkers for mild cognitive impairment and early Alzheimer's disease | Q36095322 | ||
| Huntington disease and the huntingtin protein | Q38000622 | ||
| Tau protein kinases: involvement in Alzheimer's disease | Q38022361 | ||
| An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity | Q38038981 | ||
| Invited review: Neuropathology of tauopathies: principles and practice. | Q38286208 | ||
| Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease. | Q38957994 | ||
| Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. | Q39014909 | ||
| The coexistence and differentiation of late onset Huntington's disease and Alzheimer's disease. A case report and review of the literature | Q39484690 | ||
| Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease | Q40031554 | ||
| A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10. | Q40545077 | ||
| Formation and propagation of tau oligomeric seeds | Q41820128 | ||
| Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model | Q41966030 | ||
| Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity | Q42145267 | ||
| Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms | Q42468356 | ||
| Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. | Q42654706 | ||
| Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein | Q42827866 | ||
| Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. | Q43280390 | ||
| Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. | Q45288661 | ||
| Huntington disease associated with Alzheimer disease | Q45289814 | ||
| Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity? | Q45292769 | ||
| Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington's, Alzheimer's, and Pick's diseases | Q45295797 | ||
| An immunohistochemical investigation of the human neostriatum in Huntington's disease | Q45296010 | ||
| Alzheimer-type lesions in Huntington's disease | Q45297028 | ||
| Mutant huntingtin is present in neuronal grafts in Huntington disease patients | Q45299114 | ||
| Dementia of the Alzheimer's type and Huntington's disease | Q45299681 | ||
| Huntington's disease is a four-repeat tauopathy with tau nuclear rods. | Q45300275 | ||
| Decreased expression of striatal signaling genes in a mouse model of Huntington's disease | Q45300376 | ||
| Mutant huntingtin alters Tau phosphorylation and subcellular distribution | Q45301226 | ||
| Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease | Q45303526 | ||
| Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology | Q45305215 | ||
| Biphasic developmental changes in Ca2+/calmodulin-dependent proteins in R6/2 Huntington's disease mice | Q45305873 | ||
| Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice | Q45306790 | ||
| Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation | Q46785508 | ||
| The role of MAPT sequence variation in mechanisms of disease susceptibility | Q47361624 | ||
| Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease | Q47918430 | ||
| Anatamopathological spectrum of tauopathies | Q48192397 | ||
| Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms | Q48254354 | ||
| Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells | Q48503134 | ||
| Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. | Q48521878 | ||
| An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies | Q48609551 | ||
| Modeling the relation between neurofibrillary tangles and intellectual status | Q48710392 | ||
| Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease | Q48820847 | ||
| Plaques, tangles and dementia. A quantitative study | Q48874775 | ||
| Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. | Q50856591 | ||
| Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. | Q51978000 | ||
| Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work | Q57897029 | ||
| P433 | issue | Pt 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 1014-1025 | |
| P577 | publication date | 2016-03-11 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Is Huntington's disease a tauopathy? | |
| P478 | volume | 139 |
| Q91784709 | Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms |
| Q92966000 | Dynamical decoration of stabilized-microtubules by Tau-proteins |
| Q38928751 | Faulty splicing and cytoskeleton abnormalities in Huntington's disease |
| Q36002017 | GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions |
| Q45303896 | Gray matter asymmetries in aging and neurodegeneration: A review and meta-analysis |
| Q64096404 | Involvement of T-complex protein 1-ring complex/chaperonin containing T-complex protein 1 (TRiC/CCT) in retrograde axonal transport through tau phosphorylation |
| Q41370372 | Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer's Disease and Related Tauopathies |
| Q47280331 | Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease |
| Q47104779 | Overexpression of Tau Rescues Nogo-66-Induced Neurite Outgrowth Inhibition In Vitro |
| Q45305113 | Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease |
| Q39243689 | Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases |
| Q90682346 | Spectrum of tau pathologies in Huntington's disease |
| Q36291565 | Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease? |
| Q48659268 | Tau-positive nuclear indentations in P301S tauopathy mice. |
| Q55027741 | Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders. |
| Q57021022 | The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau) |
| Q39052041 | The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases |
| Q42363775 | Wild type huntingtin toxicity in yeast: Implications for the role of amyloid cross-seeding in polyQ diseases. |
Search more.